You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Gene therapy company launched

Fidelity Biosciences, a venture capital firm that is a subsidiary of Fidelity Investments, and REGENX Biosciences, announced the formation of Dimension Therapeutics, a Cambridge gene therapy company focused on developing treatments for rare diseases such as hemophilia.

Dimension has completed an undisclosed Series A financing that was led by Fidelity Biosciences.

Continue reading below

Dimension also has entered into a collaboration with REGENX, gaining preferred access to NAV vector technology and rights in REGENX product programs.

“Gene therapy is a fundamental method of disease intervention, changing a patient’s genetic code to treat genetic disease, and in some cases providing a potential lifelong benefit following a single treatment,” said Dr. Thomas R. Beck, executive partner at Fidelity Biosciences and the interim chief executive of Dimension Therapeutics.

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week